Skip to content

Indaptus Therapeutics, Inc.

INDP

CIK 0001857044

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$15.28M
−38.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$21.41
+52.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$20.96M
Q1 May 2026
Cash
$1.5M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
113.24M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings